Atlas Trials

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Clinical trial NCT00903006 · TERMINATED

Trial details

NCT number
NCT00903006
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2009-11-01
Primary completion
2013-05-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.